logo
Plus   Neg
Share
Email

Novartis Announces Lucentis Approval In Fourth Japanese Indication - Quick Facts

Swiss pharma giant Novartis AG (NVS) announced that Lucentis (ranibizumab) has been approved by Japanese regulatory bodies for a fourth indication: to treat patients with diabetic macular edema or DME, a main cause of vision loss among patients with diabetes. Laser therapy, the current standard of care in Japan, has provided stabilization of vision in many patients, but generally does not improve vision. Lucentis is the first licensed therapy to significantly improve vision in Asian patients with visual impairment due to DME.

Tim Wright, Global Head of Development, Novartis Pharmaceuticals, said: "Lucentis has previously been shown to be an effective treatment, improving vision loss and vision-related quality of life for patients with DME." He continued, "Now Japanese patients living with DME have access to Lucentis, a drug with an unsurpassed efficacy and safety profile across multiple indications."

The Lucentis approval as based on the REVEAL trial results, the first randomized study designed specifically to evaluate the efficacy and safety of Lucentis in Asian patients with visual impairment due to DME. Efficacy and safety results from the REVEAL study were similar to other DME trials primarily conducted in Caucasians.

At 12 months, REVEAL confirmed the superior efficacy of Lucentis with rapid and sustained visual acuity gains compared with laser therapy. The safety results demonstrated that Lucentis was well tolerated in patients with DME both as monotherapy or when administered with laser.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Eli Lilly and Co. (LLY) will end a phase III clinical trial for its COVID-19 antibody treatment in the U.S., due to insufficient evidence on improved clinical outcomes. Orca Bay Foods, LLC recalled about 4,450 pounds of Trader Joe's brand Gluten Free Battered Halibut products for undeclared wheat and milk allergens, according to a statement published by the U.S. Food and Drug Administration (FDA). The action was initiated after it was discovered that product containing Wheat and Milk was distributed in packaging. Lee Kun-hee, the Chairman of South Korean conglomerate Samsung Group, has died on October 25, at the age of 78. It was he who transformed Samsung into a South Korean behemoth, and the world's largest manufacturer of smartphones, televisions, and semiconductors. As per reports, Lee's only son Jae-yong, who currently serves as vice chairman of Samsung Electronics, is likely to take over Samsung.
Follow RTT